The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 224.00
Ask: 226.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.89%)
Open: 214.00
High: 234.50
Low: 214.00
Yest. Close: 221.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Avacta enters licence deal with Werfen subsidiary Biokit

Tue, 9th Mar 2021 11:08

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.
The AIM-traded firm described Biokit as "recognised and renowned" for its experience in research, development and manufacturing of assays and biomaterial solutions for in-vitro diagnostic use.

It said the agreement followed an "extensive evaluation" by Biokit of certain Affimer reagents to detect a key analyte.

Under the terms, Biokit would have the right to develop, manufacture and commercialise a diagnostic immunoassay for the analyte through original equipment manufacturer partners.

Avacta said it would receive royalties on future sales of any products brought to market, following the completion of product development and regulatory approvals.

Financial details of the agreement were not disclosed.

"I am delighted to have established this partnership with Biokit, a world-renowned in-vitro diagnostics company, which further validates the Affimer reagent platform for diagnostics," said chief executive officer Dr Alastair Smith.

"Avacta's diagnostics business model combines development of a wholly owned pipeline of products, including the SARS-CoV-2 rapid antigen test, with licensing of Affimer reagents to diagnostic development partners such as Biokit."

Dr Smith said Biokit would develop an automated clinical assay using the Affimer reagents that Avacta had developed for them.

"There is also potential for the partnership between our two companies to continue and expand to include other diagnostic targets and future Affimer-based in-vitro diagnostics."

At 1051 GMT, shares in Avacta Group were up 2.73% at 222.93p.

More News

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

11 Jun 21 12:27

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

11 Jun 21 11:40

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

7 Jun 21 11:31

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

7 Jun 21 10:11

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

1 Jun 21 20:24

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

1 Jun 21 11:16

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

28 May 21 11:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

28 May 21 07:29

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

10 May 21 11:13

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

22 Apr 21 12:17

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 21 15:18

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20 Apr 21 12:17

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

20 Apr 21 11:35

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

15 Apr 21 14:56

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

6 Apr 21 13:53

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.